8 Massachusetts Companies Named to Fierce 15
Eight of the companies named to this year’s Fierce 15 list are based in Massachusetts, another harbinger of the biotech industry’s strength in the Commonwealth.
FierceBiotech, the biotech industry’s daily monitor, announced the 2012 Fierce 15 winners at BioPharm America™, which opened this morning at the Westin Boston Waterfront. The Fierce 15 is the hotly anticipated annual award that recognizes the 15 most promising private biotech companies in the world. The Fierce 15 celebrates the spirit of being “fierce,” championing innovation and creativity, even in the face of intense competition.
“We are thrilled that, for two years running, Massachusetts-based companies make up the majority of the Fierce 15 list,” said Robert K. Coughlin, President and CEO of MassBio, which represents more than 600 biotech companies and other industry organizations. “These companies represent the next generation of our industry—and are true examples of the Commonwealth’s position as a research and development hub. We congratulate this year’s winners and look forward to their continued success.”
Watch the announcement here.
The Massachusetts companies represented on this year’s list are:
Alkeus Pharmaceuticals (Boston)
Alkeus Pharmaceuticals is a clinical stage biotechnology company focused on discovering and developing treeatments against serious and untreatable diseases of the eye.
bluebird bio (Cambridge)
bluebird bio is developing innovative gene therapies for severe genetic disorders.
Ember Therapeutics (Boston)
Ember Therapeutics is a product-focused company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease
Enanta Pharmaceuticals (Watertown)
Enanta Pharmaceuticals is a research and development company that uses its novel chemistry approach and drug discovery capabilities to create best in class small molecule drugs in the anti-infective field.
EnVivo Pharmaceuticals (Watertown)
EnVivo is developing its broad pipeline of diverse programs with a focus on leveraging novel mechanisms of action to treat CNS diseases like schizophrenia and Alzheimer’s disease in new ways and from multiple angles.
Foundation Medicine (Cambridge)
Foundation Medicine is a molecular information company on the forefront of bringing comprehensive cancer genomic analysis to routine clinical care.
Mersana Therapeutics (Cambridge)
Mersana engineers novel drug conjugates that maximize the potential of new and established therapeutic classes. Our technology harnesses the power and synergy of nanotechnology, biologics and small molecules.
Seaside Therapeutics (Cambridge)
Seaside Therapeutics is working to correct or improve the course of autism, fragile X syndrome and other neurodevelopmental disorders by translating breakthrough discoveries in neurobiology into therapeutics that will improve the lives of patients and their families.
The full Fierce 15 list is available at www.fiercebiotech.com.
BioPharm America is the largest annual partnering conference on the East Coast. Organized by the EBD Group and hosted by MassBio, the three day event features panels & programs, company presentations and one-on-one partnering powered by partneringONE. On-site registration is available. For more information, visit www.ebdgroup.com/bpa.
Posted on September 19, 2012, in "Game Changers", MassBio, Signature Events and tagged Alkeus Pharmaceuticals, BioPharm America 2012, bluebird bio, Ember Therapeutics, Enanta Pharmaceuticals, EnVivo Pharmaceuticals, Fierce 15, FierceBiotech, Foundation Medicine, Massachusetts, Mersana Therapeutics, Seaside Therapeutics. Bookmark the permalink. 1 Comment.
Pingback: BPA 2012 Day 1 Recap « MassBioHQ